Compare GSUN & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSUN | PASG |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0M | 27.6M |
| IPO Year | 2022 | 2020 |
| Metric | GSUN | PASG |
|---|---|---|
| Price | $1.56 | $9.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | ★ 223.6K | 43.0K |
| Earning Date | 02-12-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $25,314,724.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 526.22 | N/A |
| 52 Week Low | $1.25 | $5.12 |
| 52 Week High | $5.25 | $20.20 |
| Indicator | GSUN | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | 59.07 |
| Support Level | $1.29 | $7.59 |
| Resistance Level | $1.58 | $9.20 |
| Average True Range (ATR) | 0.17 | 0.92 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 72.09 | 95.63 |
Golden Sun Health Technology Group Ltd is a holding company. Along with its subsidiaries, it is engaged in the provision of education services and e-commerce business in the People's Republic of China. It offers tutorial centers for children and adults, one educational company that partners with high schools to offer language classes to their students, and one logistics company that provides logistics and consulting services. It has also established its wellness brands and an e-commerce platform to promote and sell wellness products. The company operates in the following segments; Education, which generates maximum revenue, and E-commerce.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.